The Keio Journal of Medicine
Online ISSN : 1880-1293
Print ISSN : 0022-9717
ISSN-L : 0022-9717
CASE REPORT
A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma
Yosuke KitamuraHidehiko YoshiiKoshiro NishimotoYusuke ShinchiShigeki TokonabeMasaya TakaoYuichiro Daido
Author information
JOURNAL FREE ACCESS FULL-TEXT HTML

2015 Volume 64 Issue 4 Pages 62-64

Details
Abstract

Tyrosine kinase inhibitors such as sorafenib and axitinib were developed to treat malignancies, including stage IV renal cell carcinoma. Recently, we experienced a patient with pancreatic side effects from both sorafenib and axitinib. We report this case and include a discussion of the literature.

Content from these authors
© 2015 by The Keio Journal of Medicine
Previous article Next article
feedback
Top